This multicentre study was aimed at comparing the trough effect of telmisartan and perindopril on diastolic blood pressure (DBP), using self blood pressure measurement (SBPM). A second objective was to compare the data obtained from SBPM with those provided by automatic office BP measurement. A total of 441 mild-to-moderate hypertensive patients were randomised to receive either telmisartan 40 mg or perindopril 4 mg for a period of 12 weeks. Patients whose clinic DBP remained higher than or equal to 90 mmHg at the end of the 6th week (W6) were given a double-dose regimen. Office BP and SBPM were performed at baseline (W0), at W6 and at week 12 (W12), both with the same automatic device. A greater diminution of trough DBP was obtained with telmisartan (À6.6 7 6.7 mmHg) than with perindopril (À5.1 7 7.0 mmHg; P ¼ 0.018). Regarding clinic BP, the same results were observed. Doubling dose was significantly less frequent with telmisartan (41%; n ¼ 85) than with perindopril (55%; n ¼ 115, P ¼ 0.005). Mean values of SBPM were lower than office BP values, with a difference of a greater importance at W0 than at W12: 6.6 vs 4.7 mmHg for systolic blood pressure (Po0.005) and 3.2 vs 1.4 mmHg for DBP (Po0.0001). At W12, isolated office hypertension was found in 9% of the patients (n ¼ 37), while there were 14% of the patients (n ¼ 55) with isolated home hypertension. In conclusion, the trough effect on DBP was statistically higher with telmisartan than with perindopril. SBPM values were lower than office BP values, with greater differences before than after treatment. About a quarter of the patients were found to be controlled with a method but not with the other one.
Introduction
The superiority of self blood pressure measurement (SBPM) on traditional office levels in predicting target organ damage, 1 as well as the risk of future cardiovascular disease and mortality, has recently been demonstrated. 2 Other well-known advantages of this method are a better prediction of future blood pressure (BP) levels, 3 a higher reproducibility, 4, 5 an improvement of both BP control and patient compliance [6] [7] [8] and a suppression of the white coat effect. 9 Moreover, this method was evaluated to be cost-effective. 10 However, prospective trial data are based on office BP only, whereas SBPM would give important and useful additional information.
Accordingly, we undertook a multicentre, prospective, randomised, open study whose primary objective was to compare the trough effect of telmisartan and perindopril, using SBPM. The secondary objective of the study was to compare the data obtained from SBPM and automatic office BP measurement. This study was named EVERESTE, a French acronym meaning: EValuation de l'Efficacité RESiduelle du TElmisartan.
Methods

Study population
Men and women aged 18 years or older with both a history of mild-to-moderate essential hypertension and either inadequate BP control or treatment side effects were eligible to enter the study. The main exclusion criteria were: a history of non response to a converting enzyme inhibitor or an angiotensin II receptor antagonist, a suspicion of a secondary hypertension, obstructive biliary diseases and nonpostmenopausal women without a reliable contraceptive method.
At the end of a 3-week run-in placebo period, patients were eligible for randomisation if they had a sitting office diastolic blood pressure (DBP) greater than or equal to 90 mmHg and less than 110 mmHg and a sitting systolic blood pressure (SBP) less than 180 mmHg. The subjects with a SBPM of poor quality (less than 4 days with valid measurements instead of the 7 days requested) were excluded, as were those with a mean diastolic SBPM less than 85 mmHg. An additional exclusion criterion was a poor compliance to treatment.
Study design
This was a prospective, randomised, open, parallel group study that was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practices. The protocol was approved by the 'Comité Consultatif des Personnes se prêtant à la Recherche Biomédicale of Poitou-Charentes' and prior written informed consent was obtained from all of the subjects. After the 3-week placebo wash-out period, during which any previous antihypertensive drug treatment was discontinued, patients fulfilling inclusion criteria were randomly allocated to receive telmisartan 40 mg once daily or perindopril 4 mg once daily in the morning over a 12-week period.
Treatment allocation was performed centrally, through an interactive voice response system (IVRS), in order to reduce the chance of introducing a bias in treatment allocation. Patients whose clinic DBP remained greater than or equal to 90 mmHg at the 6th week were given a double-dose regimen.
Thus, as shown in Figure 1 , four clinical visits were scheduled during the study: selection visit (W-3), randomisation visit (W0), interim visit (W6) and final visit (W12). All of these visits took place in the morning. Patients were instructed not to take study medication on the morning of a clinic visit; on these days, study drug was administrated after measurement of office blood pressure.
Office BP measurements
BP was measured at each clinic visit using a semiautomatic device (OMRON 705 CP), which had been previously validated against the standard mercury sphygmomanometer according to the protocol of the British Hypertension Society. 11 After the patient had rested for 5 min, three BP measurements were taken at 1-min intervals with the patient in a sitting position. The mean of the three values for DBP and SBP was considered for office BP analysis.
Home SBPM
Home SBPM was performed over seven consecutive days at three different times: at the end of the washout period (W0), the week before the interim visit (W6) and the week before the final visit (W12). Measurements were standardised and two series of three consecutive measurements were requested each day: one in the morning before drug intake (between standing-up and breakfast) and one in the evening between dinner and going to bed. Recordings were performed by the patient in the sitting position after a 5-min rest using a printer-equipped semiautomatic device of the same type as that used for office BP measurement; tickets were automatically printed by the device and were pasted by the patient on an individual diary card.
The home SBPM was validated by the investigator if the patient had performed a recording during four complete days at least.
Individual SBPM was defined for each period as the mean of all available values (with the exception of those of the first day). The mean of morning measurements was considered for morning SBPM and, taking place 24 h after the previous drug intake, it gave the trough BP. The mean of evening measurements could be considered as an evaluation of the peak effect of the drug and is defined as evening SBPM. Calculations of the mean value of the different BPs were done discarding from its determination the first day measurements as well as the irrelevant values (defined as a SBP o80 or 4240 mmHg and as a DBP o40 or 4140 mmHg).
The main efficacy criterion was trough DBP (morning measurement) obtained after a 12-week treatment period adjusted on baseline DBP. The secondary criteria were evening DBP, morning and evening SBP, normalisation rates at office (DBP o90 mmHg and SBP o140 mmHg) and with SBPM (DBPo85 mmHg and SBPo135 mmHg 12 ), and correlation coefficients between office and self-measurements.
Statistical analysis
It was calculated that a total of 420 randomised patients was necessary to provide 80% power to detect a 3 mmHg (s.d. ¼ 10) difference in the final trough DBP evaluated by SBPM assuming a 20% dropout rate and two-sided testing at an overall alpha significance level of 0.05. Comparison of telmisartan and perindopril using SBPM S Ragot et al
Statistical analysis was conducted with SAS (SAS Institute, Cary, NC, USA).
Analysis of variance covariance for repeated measures was performed with Proc mixed to compare the W6 and W12 BP values or changes from baseline between the two treatment groups. Data are given as mean values 7 s.d. The values of the between-group differences (telmisartan minus perindopril) in BP reduction from baseline to W12 are given adjusted for baseline BP level and with their 95% confidence interval (CI). The differences in the rates of normalisation under treatment were assessed using the w 2 test. A comparison of office BP and SBPM was done according to the method of Bland and Altman:
13 the average of the measurements evaluated by both methods was plotted against their difference, for both SBP and DBP.
Spearman's correlation coefficients were also calculated. We report only analyses done by intention to treat (ITT). Statistical significance was set at Po0.05 (two-sided).
Results
A total of 671 patients attending 105 outpatient French centres were selected. After the 3-week placebo phase before randomisation, 441 met the inclusion/exclusion criteria and were randomised to receive either telmisartan or perindopril. The ITT population included 435 of the original 441 patients (five patients, two in the telmisartan group and three in the perindopril group were excluded because of no-assessment of home BP and office BP on active drug; furthermore, one patient did not receive the study treatment).
In all, 368 patients took part in per-protocol analysis (188 in the telmisartan group and 180 in the perindopril group). Figure 2 summarises the reasons of exclusion from the per-protocol population. Considering the ITT population, patients' mean age was 55 7 12 years (range 27-89 years), 55% were men and 97% were Caucasians. The median duration of hypertension was 1 year, and the mean BPs measured with automatic device at office at baseline was 158 7 13 and 98 7 6 mmHg for SBP and DBP, respectively. The two treatment groups were comparable with respect to all baseline characteristics (Table 1) .
Efficacy
As shown in Figure 3 , trough DBP was significantly lower in the telmisartan group than in the perindopril group when evaluated either with SBPM or with clinic measurement and both at W12 and W6. The same findings were obtained with trough SBP. Moreover, the trough pulse pressure (PP) was significantly lower in the telmisartan group than in the perindopril group at W12, when evaluated by SBPM only. Regarding evening SBPM, there was no significant difference between telmisartan and perindopril (data not shown).
The average decrease in trough DBP (value of week 12 minus value of baseline) was À6.6 mmHg for telmisartan and À5.1 mmHg for perindopril when evaluated with SBPM. Accordingly, the adjusted between-treatment difference was À1.4 mmHg (95% CI ¼ [À2.74; À0.14 mmHg]; P ¼ 0.03).
The clinic method brought to similar results with a diminution in diastolic from baseline of À8.8 mmHg with telmisartan and À6.3 mmHg with perindopril, that is, mean difference between the two treatment groups of À2.5 mmHg (95% CI ¼ [À4.11; À0.89]; P ¼ 0.002). Comparison of telmisartan and perindopril using SBPM S Ragot et al Regarding trough PP, the between-treatment difference obtained from SBPM was significant: -2 mmHg (95% CI ¼ [À3.44; À0.54]; P ¼ 0.007). By contrast no significant difference was found with clinic measurement: À1 mmHg (95% CI ¼ [À3.17; 1.14]; NS).
Normalisation rates are given in Table 2 . The DBP normalisation rates with telmisartan were higher than those with perindopril at W12 and at W6 whatever the method of measurement. As a consequence, doubling dose was significantly less frequent with telmisartan (41%; n ¼ 85) than with perindopril (55%; n ¼ 115, P ¼ 0.005). Table 3 provides information about the agreement between the two methods of measurement. Considering the overall ITT population, mean values of SBP, DBP and PP obtained by SBPM were significantly lower than those obtained by automatic office BP both at W0 and W12. However, there was a weak but nonetheless statistically significant linear correlation between the two methods of measurement. The stronger correlation was observed for PP at W12. For SBP and DBP, the mean differences between the methods were significantly lower at W12 than at W0 (P paired test o0.005 for SBP and o0.0001 for DBP). The 95% CI of the betweenmethod differences was large: always greater than 30 mmHg and of more than 50 mmHg for SBP at W0. Figure 4 represents the comparison of both measurement methods for DBP at W0 and at W12 according to the method of Bland and Altman. Figure 5 shows the distribution of normalised and non-normalised patients according to both methods. The discrepancies between the two methods were balanced for SBP and this is not the case for DBP where the most frequent DBP discrepancies were related to patients who were normalised according to office measurement and not normalised according to SBPM.
Agreement between the two methods
At the end of the study, 37 patients were found with isolated office hypertension, that is, 9% of our population study, while there were 55 patients, that is, 14%, with isolated home hypertension.
Feasibility
The rate of patients excluded from ITT population for insufficient SBPM quality was 3.7% (nine patients in the telmisartan group and seven patients in the perindopril group) before W0 and 9.9% (18 patients in the telmisartan group and 25 in the perindopril group) before W12. A poor quality of SBPM resulted in 81% of the exclusions from perprotocol population. Comparison of telmisartan and perindopril using SBPM S Ragot et al Table 4 gives, for each visit and for all of the visits, the number of patients who performed a complete (six measurements per day) SBPM over a total of 7 days or 4 days. Considering independently each visit, about one-half of the patients was able to record BP for 7 days and less than 30% were able to do so for all visits. The sequence of 4 days showed a greater feasibility: accordingly, almost 90% of the patients recorded a complete sequence of 4 days at each of the three visits.
Adverse events
The overall incidence of adverse events was comparable in both treatment groups: 34% (n ¼ 74) with telmisartan and 32% (n ¼ 70) with perindopril. Most of them were of mild-to-moderate intensity and transient. As expected, the occurrence of cough was more frequent with perindopril: 5% (n ¼ 12) than with telmisartan: o1% (n ¼ 2), P ¼ 0.007. Comparison of telmisartan and perindopril using SBPM S Ragot et al
Discussion
Antihypertensive effect of telmisartan and of perindopril
In the present study, telmisartan 40 mg produced clinically relevant decreases in trough DBP, SBP and PP that were slightly but significantly greater than those produced by perindopril both with SBPM and with automatic office measurement. Categorical analysis of DBP and SBP rates of normalisation confirmed these differences in favour of telmisartan. However, considering the absence of statistical difference in evening BP between the two treatment groups, these data have to be understood as a more sustained antihypertensive effect rather than as a greater efficacy of telmisartan, in comparison with perindopril.
The antihypertensive efficacy of telmisartan has been shown in clinical studies using measurement office BP, to be at least equivalent to that of angiotensin-converting enzyme inhibitors, namely: lisinopril in mild-to-moderate hypertensive patients, 14 enalapril in mild-to-moderate hypertensives, 15, 16 in severe hypertensives 17 and in elderly patients. 18 Interestingly, telmisartan was described by Mallion et al 19 to be more effective in lowering SBP and DBP during the 18 to 24-h postdose period than was losartan using ambulatory BP monitoring. 19 Likewise, a greater reduction in ambulatory DBP was found with telmisartan than with amlodipine during the night time interval and the last 4 h of the design period in a study by Lacourcière et al.
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Of note, doubling the dosage of both telmisartan and perindopril resulted in a very low increase in the number of normalised patients. Obviously, in clinical practice, the most efficient strategy in the presence of a poor response to monotherapy should be not to increase the dose, but to add a diuretic or to shift to another drug, acting through a different mechanism. Accordingly, Lacourcière et al 21 showed that a 'telmisartan 80 mg/HCTZ 12.5 mg fixed dose combination confers significant additional BP reductions compared with continuation of telmisartan monotherapy in nonresponders' (41.5% of patients with normalised BP in the combination treatment group vs 26.1% in telmisartan group; Po0.05), Furthermore, in a recent crossover study by Dickerson et al, 22 a significant correlation was found between the BP responses to angiotensinconverting enzyme inhibitors and betablockers, as well as between those to calcium channel blockers and diuretics, but not between the other four pairing of treatments. Then it could be speculated that patients who fail to respond to renin-angiotensin system blockade should be subsequently given a calcium channel blocker or a diuretic (and conversely).
Comparison of office and home BP measurements
Considering the average BP values, we found along with other authors that home BP levels were lower than their corresponding office values with a difference of 1.4 mmHg for DBP and of 4.7 mmHg for SBP at the end of the study. Before treatment (visit W0) these differences were larger: 3.2 mmHg for DBP and 6.6 mmHg for SBP. These findings are in keeping with the existing published data:
* In a previous study 23 aimed at comparing the antihypertensive effects of trandolapril and losartan in 229 hypertensives, we found a difference of 1.3 and 8.9 mmHg for DBP and SBP, respectively, under treatment and of 11.2 and 17.5 mmHg before treatment. The between-method differences , patients normalised according to office measurement only (isolated home hypertension);
, patients normalised according to SBPM only (isolated office hypertension). 25 has reported very slight differences between office and home values of about 0.2 mmHg for DBP and 0.5 mmHg for SBP, at a time when the titration of antihypertensive medication had been finalised. Despite the small size of the mean differences, the 95% limits of agreement between the two methods were very large, as compared with those of the present study: À17.4 to 17.9 mmHg for DBP and À29.5 to 30.5 mmHg for SBP. In addition, the correlation between the two methods was rather low: 0.35 for DBP and 0.45 for SBP, vs 0.54 and 0.70 in our study. The differences between the two studies could be partly because of the conditions of measurement both at home and in the office: (1) the semiautomatic device used in the HOT study was not print-equipped; (2) measurements were not standardised for intake of antihypertensive medication; (3) the morning measure had to be done before leaving home and the evening determination was required in the afternoon after returning home. Obviously, the findings of Kjeldsen's substudy, as well as those of the present study, point out the irrelevance of an individual extrapolation of office BP measurement to home BP readings.
Concerning the attenuation of the difference between office BP and SBPM with drug intake, it could be interesting to refer to a study by Parati et al, 26 related to the effects of calcium channel blockers and ACE inhibitors vs placebo, on the differences between clinic BP measurement and ambulatory BP monitoring. In their experience, the greater the baseline between-method difference, the greater the treatment-induced reduction in this difference; furthermore, they showed placebo to have an effect of the same magnitude than did pharmacological drugs on the clinic-ambulatory difference, suggesting either a habituation of the patients to clinic BP measure, or a regression towards the mean, or both. Of course, the same explanations could be given as to the differences between clinic BP and SBPM. Accordingly, Imai et al 27 considered the magnitude of regression towards the mean to be rather small for SBPM.
While a large body of literature has demonstrated the lack of prognostic significance of the white coat effect, there are still no clear information about the prognosis of patients with normal clinic BP and elevated ambulatory or self-measured BP. Of note, we found in our study an unexpected high rate of patients with isolated home BP at the end of the study. A cross-sectional study 28 has suggested these patients to be at a higher cardiovascular risk, as long as they have been found with more risk factors and a more frequent history of cardiovascular diseases, in comparison with other patients. However, we should have to wait for 3 years to know whether this hypothesis is confirmed or not, by a longitudinal approach.
Feasibility
SBPM feasibility is currently considered as good, even if it has been said that SBPM technique needs a greater physician involvement and a selection of appropriate patients to comply with the SBPM protocol. Our study confirms the good feasibility of this technique; however, a SBPM poor quality recording was the reason why 16 and 43 patients (81%) had to be excluded from the per-protocol population, before randomisation and before the end of the study, respectively.
The monitoring schedule defined for this study consisted of six measurements per day over a total of 7 days: such a design is not in agreement with the most recent recommendations, which suggest to perform four to six measurements a day over a 3 to 4-day period. 12 
Study limitations
The main limitation of this study is related to the lack of blinded drug allocation. Such an open-label design has been arbitrarily chosen. However, BP measurements were performed under standardised conditions and using automatic machines, which should avoid bias in the primary end point of the study. In contrast, the knowledge of drug allocation could have resulted in an impact of tolerability assessment. Interestingly, in a double-blind study, a cough incidence of 6.5% has been reported in patients receiving telmisarten vs 15.8% in those receiving enalapril; 29 in another randomised doubleblind study, a treatment-related cough was found in none of the patients who were given 40-80 mg of telmisartan, whereas it occurred in 4.2% of patients on enalapril and in 1.3% of patients on placebo. 16 
